Results 141 - 150 of 185
Researchers
Explore mentor profiles by selecting a name below. Each profile includes information about research interests, lab affiliations, publications, and additional details about their work and expertise.
| Name | Track | Location | View profile |
|---|---|---|---|
| Clinical and Translational Science | Minnesota | ||
IntroductionDr. Sharp's current research examines how patients and healthcare providers view new forms of personalized medicine and clinical interventions enabled by molecular diagnostics and digital health technologies. |
|||
| Molecular Pharmacology and Experimental Therapeutics | Minnesota | ||
IntroductionThis research program has, over the years, sequentially incorporated advances in analytical techniques to identify and study individual variation in the pharmacologic therapy of disease, with special emphasis on neuropsychiatric disorders such as Major Depressive Disorder (MDD) or Alcohol Use Disorder (AUD). These studies have resulted in the identification of novel genes responsible for variation in disease pathophysiology as well as novel pathways for drug response and new drug development. |
|||
| Biochemistry and Molecular Biology, Clinical and Translational Science, Immunology, Molecular Pharmacology and Experimental Therapeutics, Virology and Gene Therapy | Minnesota | ||
Introduction
Dr. Patel's research focuses on microbial biofilms and antibacterial resistance. Her lab focuses on new diagnostics and therapeutics for biofilm-associated infections, including periprosthetic joint infections, endocarditis, catheter-associated infections and wound infections. She also focuses on evaluation of new antibacterial therapies in vitro and in vivo, emerging pathogens and their pathogenesis, and diagnostic approaches that address antibacterial resistance.
|
|||
| Biomedical Engineering and Physiology | Minnesota | ||
IntroductionOur lab is very interested in the clinical intersection of human autonomic physiology and how this is impacted by spinal cord injury. Typically, most people focus on the visible manifestations of paralysis, yet we have characterized significant autonomic impairments. These autonomic impairments better predict who will develop meaningful health declines - helping direct improved future clinical care. |
|||
| Biochemistry and Molecular Biology, Biomedical Engineering and Physiology, Clinical and Translational Science | Minnesota | ||
IntroductionWelcome to the Lipotoxicity and Liver Inflammation Laboratory. Our collaborative and dynamic team investigates the cellular and molecular mechanisms driving metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), with a focus on hepatocyte injury, liver sinusoidal endothelial cell dysfunction, inflammation, and ferroptosis. Our goal is to translate mechanistic discoveries into novel therapeutic strategies for liver disease. Mentees receive individualized mentorship and opportunities to develop skills in experimental design, scientific communication, and translational research. |
|||
| Biochemistry and Molecular Biology, Immunology, Neuroscience, Regenerative Science | Florida | ||
IntroductionThe diverse team of researchers led by Dr. Da Mesquita is focused on determining and testing the factors that increase the risk for neurological diseases by mediating long-lasting changes in the meningeal lymphatic vasculature and in central nervous system immunity. Employing complementary approaches including genetically modified mice, human tissue and fluid samples, and state-of-the-art techniques, like in vivo fluorescence microscopy, flow cytometry, and single-cell RNA sequencing, Dr. Da Mesquita and his team aim at understanding how the meningeal lymphatic vasculature modulates brain function along the mammalian lifespan, and is able to affect the progression and outcome of neurodegenerative diseases like Alzheimer’s and Parkinson's. |
|||
| Immunology | Arizona | ||
IntroductionI am a professor in Immunology, Mayo Clinic Arizona. My research is focusing on the discovery of immune regulatory function of B and dendritic cells for the rational desing of novel therapeutic strategies for inflammatory diseases, including autoimmmune dises, and transplantation rejection. |
|||
| Molecular Pharmacology and Experimental Therapeutics | Minnesota | ||
IntroductionMy goal is to improve the therapy of neoplastic diseases, focusing on acute leukemias and ovarian cancers. As a mentor, I strive to see that my trainees learn to recognize and address impactful problems, conduct rigorous and insightful experiments, and pursue answers to their questions wherever the science leads. Previous postdoctoral fellows from the laboratory are serving as cancer center directors (two) or leading research activities in academia or biotech. Previous Ph.D. students from the laboratory are leading major efforts in biotech or running their own independent laboratories in academia. |
|||
| Molecular Pharmacology and Experimental Therapeutics | Minnesota | ||
IntroductionMy laboratory studies the mechanism of action of targeted anti-cancer agents and factors that affect tumor cell response. Our research goals are to: i) Understand the processes by which targeted anti-cancer agents kill susceptible tumor cells; ii) elucidate the steps involved in transmitting signals from the initial drug target to the cytotoxic machinery within cells; iii) determine how differences in these signaling steps from one tumor to another impact response; and iv) develop biomarkers of anti-cancer drug sensitivity and resistance that can be implemented in the clinic. While our research focuses predominantly on ovarian cancers and acute leukemias, our research findings are potentially applicable to other types of cancer as well. |
|||
| Clinical and Translational Science | Arizona | ||
IntroductionDr. Shannon Fortin Ensign is a Neuro-Oncologist and Physician-Scientist at Mayo Clinic whose translational research focuses on the molecular mechanisms driving glioma progression and therapeutic resistance, particularly in IDH-mutant astrocytoma. Her lab integrates functional genomics, cell signaling, spatial and single-cell transcriptomics, and patient-derived datasets to define tumor–microenvironment interactions that promote disease progression, with the goal to uncover therapeutic vulnerabilities. Her group seeks to identify biologically informed therapeutic targets and biomarkers to inform future treatment strategies and clinical trial development. She is committed to mentoring the next generation of scientists. |
|||